The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study.
 
Valeriy Vladimirovich Breder
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; MSD Oncology; Roche; Takeda
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; MSD Oncology; Roche; Takeda
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Ipsen; Roche; Takeda
 
Arndt Vogel
Honoraria - Amgen; Bristol-Myers Squibb; Ipsen; Janssen; Lilly; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Baxalta; Bayer; BTG; Eisai; IPSEN; Lilly; Novartis; Pierre Fabre; Roche
Research Funding - Novartis
Travel, Accommodations, Expenses - Bayer; Ipsen; Roche
 
Philippe Merle
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Lilly; Merck Sharp & Dohme; Roche
Research Funding - Ipsen (Inst)
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Ipsen; Roche
 
Richard S. Finn
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CStone Pharmaceuticals; Eisai; Exelixis; Genentech/Roche; Lilly; Merck; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Expert Testimony - Bayer
 
Peter R. Galle
Honoraria - Adaptimmune; Bayer Schering Pharma; Bristol-Myers Squibb; Ipsen; Lilly; MSD; Roche/Genentech; Sirtex Medical
Consulting or Advisory Role - Adaptimmune; Bayer Schering Pharma; Bristol-Myers Squibb; Lilly; MSD; Roche/Genentech; Sirtex Medical
Speakers' Bureau - Bayer Schering Pharma; Ipsen; Lilly; Roche
Travel, Accommodations, Expenses - Bayer Schering Pharma; Lilly; Sirtex Medical
 
Andrew X. Zhu
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; Exelixis; Gilead Sciences; Gilead Sciences; Lilly; Merck; Roche/Genentech; Sanofi/Aventis
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)
 
Ann-Lii Cheng
Honoraria - AstraZeneca; Bayer Health; BeiGene; Bristol-Myers Squibb; CSR Pharma; Eisai; Exelixis; Ipsen; IQVIA; Merck Serono; Merck Sharp & Dohme; Novartis; Nucleix; Ono Pharmaceutical; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Bayer Health; BeiGene; Bristol-Myers Squibb; CSR Pharma; Eisai; Exelixis; Ipsen; IQVIA; Merck Serono; Merck Sharp & Dohme; Novartis; Nucleix; Ono Pharmaceutical; Roche/Genentech
Speakers' Bureau - Amgen; Bayer Yakuhin; Eisai; Novartis; Ono Pharmaceutical
Travel, Accommodations, Expenses - IQVIA; Roche/Genentech
 
Yin-Hsun Feng
Research Funding - Kirin Pharmaceuticals
Travel, Accommodations, Expenses - Pfizer; Roche; Takeda
 
Daneng Li
Consulting or Advisory Role - Advanced Accelerator Applications; Eisai; Exelixis; Genentech; Ipsen; Lexicon; MINA THERAPEUTICS; QED Therapeutics; Taiho Pharmaceutical
Speakers' Bureau - Advanced Accelerator Applications; Coherus Biosciences; Eisai; Exelixis; Ipsen; Lexicon; Sun Pharma
Research Funding - Brooklyn ImmunoTherapeutics (Inst)
 
Vincent E. Gaillard
Employment - Roche
Stock and Other Ownership Interests - Roche
Travel, Accommodations, Expenses - Roche
 
Lindong Li
Employment - Roche
 
Alan Nicholas
Employment - Genentech
Stock and Other Ownership Interests - Genentech
 
Riccardo Lencioni
Consulting or Advisory Role - Celsion; Eisai; Roche/Genentech
Research Funding - AstraZeneca